Proton therapy for Hodgkin lymphoma.

Area of Science:

• Oncology
• Radiation Oncology
• Medical Physics

Background:

• Hodgkin lymphoma treatment has evolved from incurable to highly curable, leading to a growing population of long-term survivors.
• Long-term survivors often face severe late treatment-related complications, including cardiovascular disease and secondary malignancies.
• Current research focuses on maintaining high disease control rates while reducing treatment-related morbidity and mortality.

Purpose of the Study:

• To review the scientific basis for the advantages of proton therapy compared to conventional X-ray therapy for Hodgkin lymphoma.
• To discuss the outcomes of Hodgkin lymphoma patients treated with proton therapy.
• To evaluate the potential of proton therapy in reducing radiation dose to organs at risk and mitigating significant late complications.

Main Methods:

• Review of existing literature on proton therapy for Hodgkin lymphoma.
• Analysis of studies comparing proton therapy outcomes with conventional radiotherapy.
• Evaluation of dosimetric benefits of proton therapy in reducing radiation exposure to critical organs.

Main Results:

• Proton therapy demonstrates the potential to significantly reduce radiation dose delivered to organs at risk compared to conventional X-ray therapy.
• Early outcomes suggest that proton therapy can maintain high disease control rates in Hodgkin lymphoma.
• Reduced radiation dose is anticipated to decrease the incidence and severity of long-term treatment-related complications.

Conclusions:

• Proton therapy represents an advancement in radiation oncology for Hodgkin lymphoma, offering a way to improve long-term quality of life for survivors.
• The ability of protons to precisely target tumors while sparing healthy tissues is key to reducing late toxicities.
• Further research and clinical implementation of proton therapy are warranted to optimize Hodgkin lymphoma treatment strategies.